Entrada Therapeutics Inc
NASDAQ:TRDA
Entrada Therapeutics Inc
Common Stock
Entrada Therapeutics Inc
Common Stock Peer Comparison
Competitive Common Stock Analysis
Latest Figures & CAGR of Competitors
Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Entrada Therapeutics Inc
NASDAQ:TRDA
|
Common Stock
$3k
|
CAGR 3-Years
-97%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Common Stock
$18m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Common Stock
$1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Common Stock
$33.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Common Stock
$2.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
3%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Common Stock
$101.8k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Entrada Therapeutics Inc's Common Stock?
Common Stock
3k
USD
Based on the financial report for Dec 31, 2023, Entrada Therapeutics Inc's Common Stock amounts to 3k USD.
What is Entrada Therapeutics Inc's Common Stock growth rate?
Common Stock CAGR 3Y
-97%
The average annual Common Stock growth rates for Entrada Therapeutics Inc have been -97% over the past three years .